跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,064 条关于
“XtalPi Holdings”
全部
1,064
临床试验
104
药物
64
机构
151
资讯
745
去年
XtalPi Secures $100 Million Partnership with Harvard's Gregory Verdine to Advance AI-Driven Drug Discovery
3个月前
XtalPi's AI-Designed Peptide Receives US Safety Certification While Pan-TEAD Inhibitor Advances to Clinical Trials
4个月前
XtalPi-Enabled PRMT5 Inhibitor PEP08 Reaches Phase I Enrollment Milestone in Solid Tumor Trial
去年
Sareum's SDC-1801 Advances to Phase II Trials for Psoriasis Following Positive Phase I Results
去年
XtalPi's AI-Designed PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals for Solid Tumors
去年
European Commission Approves Novo Holdings' $16.5B Catalent Acquisition
2年前
Bio-Path Holdings' BP1003 Demonstrates Therapeutic Potential in Diverse Cancers
2年前
Immunocore and Bristol Myers Squibb Collaborate on Phase 3 Trial for Advanced Cutaneous Melanoma
去年
ALX Oncology's Evorpacept Shows Promise in Multiple Cancer Trials
去年
CERO Therapeutics' CER-1236 Receives FDA Clearance for Clinical Trials
第 1 页,共 75 页
上一页
下一页